Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

83.62 -0.45 (-0.54%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,672,080
Open 83.76
Bid (Size) 83.36 (1)
Ask (Size) 83.41 (1)
Prev. Close 84.07
Today's Range 82.61 - 83.81
52wk Range 57.16 - 89.74
Shares Outstanding 1,253,809,440
Dividend Yield 3.40%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Could Gilead Sciences Stock Help You Become a Millionaire?
Does Gilead have enough growth potential to become a market-beating investment? 
Via The Motley Fool
3 Smart Stocks to Buy if a Recession Is on the Way
Their products will enjoy strong demand regardless of what happens with the economy. 
Via The Motley Fool

Performance

YTD
-2.07%
-2.07%
1 Month
-1.64%
-1.64%
3 Month
+18.07%
+18.07%
6 Month
+37.31%
+37.31%
1 Year
+21.47%
+21.47%

More News

Read More
Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023
From Gilead Sciences, Inc.
Via Business Wire
16 Analysts Have This to Say About Gilead Sciences
Via Benzinga
3 Stocks That Beat the S&P During the Great Recession
Via The Motley Fool
Mount Gilead, NC Author Publishes Children's Book
Via PR Leap
If You Invested $100 In This Stock 15 Years Ago, You Would Have $400 Today
Via Benzinga
This New Drug Could Be Gilead Sciences' Growth Catalyst
Via The Motley Fool
J.P.Morgan Healthcare Conference JPM23: Biotech Rally Favors Smaller Caps
Via Talk Markets
Cell and Gene Therapy Market Size, Share, Industry Analysis, Growth Estimates, Trends, Demand and Forecast 2022-2028
Via SBWire
Peering Into Gilead Sciences's Recent Short Interest
Via Benzinga
2 Unstoppable Stocks That Could Beat the Market Again In 2023
Via The Motley Fool
Can The No. 1 Pharma Stock, Merck, Continue Its Blazing Run In 2023?
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
Via Benzinga
European Medicines Agency Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
From Gilead Sciences, Inc.
Via Business Wire
Better Large-Cap Buy: Roche Holding or Gilead Sciences Stock?
Via The Motley Fool
FTX Exchange's Assets Worth $3.5B Held By Bahamian Regulators, Italy PM To Meet Intel Over Chip Investment, New Oral COVID Antiviral Might Be Better Than Pfizer's Paxlovid: Today's Top Stories
Via Benzinga
New Oral COVID-19 Antiviral Might Be Better Than Pfizer's Paxlovid With Faster Recovery, Fewer Side Effects, Data Shows
Via Benzinga
3 High-Yielding Dividend Stocks That Could See Hikes in January
Via The Motley Fool
Gilead Sciences Acquires Jounce Therapeutics Cancer Immunotherapy Program
Via Benzinga
Why Is Jounce Therapeutics (JNCE) Stock Up 70% Today?
Via InvestorPlace
Tesla, Apple, Lightjump, Southwest, Gilead: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics
From Gilead Sciences, Inc.
Via Business Wire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.